Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > "The reality is the boats are shaking"

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 06, 2024 3:32pm

175 Views

Post# 35813991

RE:RE:RE:RE:RE:RE:"The reality is the boats are shaking"

So it could well be that both ONCY and PANCAN are awaiting the FDA's Feburary 14, 2024 PDU on Ipen's sNDA with the Onivyde regimen in first line mPDAC patients before moving forward with pelareorep + the immune checkpoint inhibitor Tecentriq + chemotherapy in a Phase 3 (post approval /confirmatory) trial in first-line mPDAC patients.

ONCY's / PanCan's Phase 2 pelareorep + immune checkpoint inhibitor Tecentriq + Folfirinox clinical trial in first line mPDAC patients would be an added benefit to the earlier putative approval.

<< Previous

Bullboard Posts

Next >>

Junior helium miner will explore record discovery in Q4